Abstract
Fasting insulin is related to outcome in early breast cancer. We evaluated the expression of insulin receptor (IR) and its prognostic significance in patients with early stage breast cancer. Tumors from 191 patients with T1-3, N0-1, M0 breast cancer who were enrolled at a single center of a multicenter cohort study were used to construct microarrays with subsequent immunohistochemical evaluation of IR, IGF-IR, ER, PgR and HER2/neu. Correlation of biomarker expression with traditional prognostic factors, serum biochemistry (notably insulin) and clinical outcome was assessed. IR was strongly positive (Allred score = 8) in 54% of tumors. High IR expression significantly correlated with favorable prognostic markers (low tumor grade, lymph node negativity and progesterone receptor positivity) but not with fasting levels of circulating insulin. At a median follow-up of 9.1 years, high vs. low IR expression (an Allred score of 8 vs. 0-7) was associated with statistically significant improved distant disease-free survival (multivariate hazard ratio (HR) = 0.4; P = 0.027) and overall survival (multivariate HR = 0.26; P = 0.005). IR is highly expressed in the majority of early stage breast cancers but this expression is not clearly down-regulated in the presence of high insulin levels. Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended.
Similar content being viewed by others
References
Scheen AJ, Lefebvre PJ (1996) Insulin action in man. Diabetes Metab 22: 105-110
Whitelaw DC, Gilbey SG (1998) Insulin resistance. Ann Clin Biochem 35 (Pt 5):567-583
Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212
Bentel JM, Lebwohl DE, Cullen KJ et al (1995) Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells. J Cell Physiol 165:212-221
Gliozzo B, Sung CK, Scalia P et al (1998) Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway. J Cell Biochem 70:268-280
Pollak M, Costantino J, Polychronakos C et al (1990) Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-1697
Yang XF, Beamer WG, Huynh H, Pollak M (1996) Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 56:1509-1511
Goodwin PJ, Ennis M, Pritchard KI et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42-51
Borugian MJ, Sheps SB, Kim-Sing C et al (2004) Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomarkers Prev 13:1163-1172
Pasanisi P, Berrino F, De Petris M et al (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119:236-238
Pollak MN, Chapman JW, Shepherd L et al (2006) Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J Clin Oncol (Meet Abstr) 24:524
Belfiore A, Frittitta L, Costantino A et al (1996) Insulin receptors in breast cancer. Ann NY Acad Sci 784:173-188
Papa V, Belfiore A (1996) Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 19:324-333
Milazzo G, Yip CC, Maddux BA, Vigneri R, Goldfine ID (1992) High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells. J Clin Invest 89:899-908
Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R (1997) Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109:565-571
Frasca F, Pandini G, Scalia P et al (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288
Froesch ER, Schmid C, Schwander J, Zapf J (1985) Actions of insulin-like growth factors. Annu Rev Physiol 47:443-467
Rechler MM, Nissley SP (1985) The nature and regulation of the receptors for insulin-like growth factors. Annu Rev Physiol 47:425-442
Bruning PF, Bonfrer JM, van Noord PA et al (1992) Insulin resistance and breast-cancer risk. Int J Cancer 52:511-516
Del Giudice ME, Fantus IG, Ezzat S et al (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111-120
Gamayunova VB, Bobrov Y, Tsyrlina EV, Evtushenko TP, Berstein LM (1997) Comparative study of blood insulin levels in breast and endometrial cancer patients. Neoplasma 44:123-126
Yam D, Fink A, Mashiah A, Ben Hur E (1996) Hyperinsulinemia in colon, stomach and breast cancer patients. Cancer Lett 104:129-132
Plymate SR, Jones RE, Matej LA, Friedl KE (1988) Regulation of sex hormone binding globulin (SHBG) production in Hep G2 cells by insulin. Steroids 52:339-340
Peiris AN, Sothmann MS, Aiman EJ, Kissebah AH (1989) The relationship of insulin to sex hormone-binding globulin: role of adiposity. Fertil Steril 52:69-72
Adlercreutz H (1990) Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 201:3-23
El Tanani MK, Green CD (1996) Oestrogen and insulin interact at the level of transcription in breast cancer cells. Biochem Soc Trans 24:343S
Nagarajan L, Anderson WB (1982) Insulin promotes the growth of F9 embryonal carcinoma cells apparently by acting through its own receptor. Biochem Biophys Res Commun 106:974-980
Lupulescu AP (1985) Effect of prolonged insulin treatment on carcinoma formation in mice. Cancer Res 45:3288-3295
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168
Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
Mohsin SK, Weiss H, Havighurst T et al (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17:1545-1554
O’Malley FP, Parkes R, Latta E et al (2001) Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 115:504-511
Liu CL, Prapong W, Natkunam Y et al (2002) Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 161:1557-1565
Papa V, Pezzino V, Costantino A et al (1990) Elevated insulin receptor content in human breast cancer. J Clin Invest 86:1503-1510
Bonneterre J, Peyrat JP, Beuscart R, Demaille A (1990) Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50: 6931-6935
Foekens JA, Portengen H, Janssen M, Klijn JG (1989) Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63:2139-2147
Papa V, Gliozzo B, Clark GM et al (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736-3740
Railo MJ, von Smitten K, Pekonen F (1994) The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311
Arteaga CL, Osborne CK (1989) Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49:6237-6241
Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D (2006) Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66:2391-2402
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mulligan, A.M., O’Malley, F.P., Ennis, M. et al. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106, 39–47 (2007). https://doi.org/10.1007/s10549-006-9471-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9471-x